Alzheimers Disease Clinical Trial
Official title:
A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02409082 -
Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures
|
N/A | |
Terminated |
NCT02565511 -
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
|
Phase 2/Phase 3 | |
Completed |
NCT01993836 -
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
|
Phase 4 | |
Terminated |
NCT05097131 -
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
|
||
Completed |
NCT00448799 -
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
|
Phase 1 | |
Terminated |
NCT06424236 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05891496 -
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
|
Phase 3 | |
Terminated |
NCT01733355 -
A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807
|
Phase 0 | |
Terminated |
NCT01723488 -
A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
|
Phase 0 | |
Completed |
NCT00911690 -
Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders
|
N/A | |
Recruiting |
NCT01479855 -
Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type
|
N/A | |
Completed |
NCT01469351 -
Identifying Potential Effects of Liraglutide on Degenerative Changes
|
N/A | |
Completed |
NCT00439010 -
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05269394 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
|
Phase 2/Phase 3 | |
Recruiting |
NCT01760005 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
|
Phase 2/Phase 3 | |
Completed |
NCT04623242 -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
|
Phase 2/Phase 3 | |
Suspended |
NCT05552157 -
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
|
Phase 2/Phase 3 | |
Completed |
NCT04023994 -
A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants
|
Phase 1 | |
Terminated |
NCT03131453 -
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
|
Phase 2/Phase 3 | |
Completed |
NCT01946243 -
The Feasibility of Florbetapir Quantitation
|
Phase 4 |